Status:
COMPLETED
Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes
Lead Sponsor:
Walter Reed Army Medical Center
Conditions:
Healthy
Eligibility:
All Genders
18-50 years
Brief Summary
The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.
Eligibility Criteria
Inclusion
- Adult active duty personnel between 18 and 50 years of age with best corrected visual acuity of 20/20 or better.
Exclusion
- Patients not meeting above stated age criteria
- Females that are pregnant or lactating (non pregnant females of childbearing potential will have pregnancy test prior to participating in study)
- History of serious ocular, neurological, cardiovascular disease
- History of severe systemic disease
- History of arrhythmias or high blood pressure
- Patients currently taking any type of ocular or systemic medications except multivitamins.
- Patients with abnormal pupil shape, Addie's pupil, anisocoria, or abnormal pupil defect.
Key Trial Info
Start Date :
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00413751
Last Update
December 20 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Walter Reed Army Medical Center
Washington D.C., District of Columbia, United States, 20307